Nadide
Nadide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adstiladrin | Biologic Licensing Application | 2024-10-30 |
| allevia | unapproved drug other | 2025-02-27 |
| as i am | C200263 | 2024-10-09 |
| co-bb-52549 featuring you hydrating skin enhancing tint spf30-375 strength co-bb-52816 featuring you hydrating skin enhancing tint spf30-390 achiev... | C200263 | 2024-04-01 |
| converthera nad plus patch | unapproved drug other | 2025-07-18 |
| detijian nadh | unapproved drug other | 2022-02-21 |
| enbrace hr | unapproved drug other | 2025-01-02 |
| enlyte | unapproved drug other | 2022-07-01 |
| nadolol | ANDA | 2025-08-29 |
| nadolol and bendroflumethiazide | ANDA | 2016-04-15 |
Show 3 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1089 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 1 | — | — | — | 5 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | — | — | — | — | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | — | — | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | 2 | — | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nadide |
| INN | nadide |
| Description | Nicotinamide adenine dinucleotide (NAD) is a coenzyme central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other, nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH (H for hydrogen), respectively.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 53-84-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1234613 |
| ChEBI ID | 44215 |
| PubChem CID | 925 |
| DrugBank | DB00157 |
| UNII ID | 0U46U6E8UK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 65 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enlyte
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58,711 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use